Abstract

Review Article

COVID-19: Targeting the cytokine storm via cholinergic anti-inflammatory (Pyridostigmine)

Ahmed H Osman*

Published: 21 May, 2020 | Volume 4 - Issue 1 | Pages: 041-046

Background: The development of COVID-19 having been set apart as the third presentation of an exceptionally pathogenic coronavirus into the human populace after the extreme intense SARS-COV and MERS-COV in the twenty-first century. The infection itself doesn’t make a crucial commitment to mortality, anyway “cytokine storm” created by the unreasonable invulnerable reaction activated by the virus can result in a hyperinflammatory response of lung tissues and deadly lung injury, and in this way increment death rate. In this manner, immunomodulatory medications ought to likewise be remembered for treatment of COVID-19.

Presentation of the hypothesis: the virus particles invade the respiratory mucosa firstly and infect other cells, triggering a series of immune responses and the production of cytokine storm in the body, which may be associated with the critical condition of COVID-19 patients. Once a cytokine storm is formed, the immune system may not be able to kill the virus, but it will certainly kill many normal cells in the lung, which will seriously damage the of lung function. Patients will have respiratory failure until they die of hypoxia. It is not yet clear what the death rate of Covid-19 will be, though the best estimate right now is that it is around 1 percent, 10 times more lethal than seasonal flu due to cytokines storm which trigger a violent attack by the immune system to the body, cause acute respiratory distress syndrome (ARDS) and multiple organ failure, and finally lead to death in severe cases of COVID-19 infection. Therefore, inhibiting cytokine storm can significantly reduce inflammatory injury in lung tissues.

Pyridostigmine (PDG), cholinergic anti-inflammatory pathway (CAP) is a neural mechanism that modulates inflammation through the release of acetylcholine (ACh), resulting in decreased synthesis of inflammatory cytokines such as TNF-α and IL-1. This finding emphasis, the nervous and immune systems work collaboratively during infection and inflammation.

Implications of the hypothesis: Administrations of Pyridostigmine (PDG) as cholinergic agonist inhibits the inflammatory response and lower the mortality of COVID-19 patients. Likewise, activation of the CAP during systemic inflammation down-regulates the production and release of inflammatory cytokines. 

Read Full Article HTML DOI: 10.29328/journal.ijcv.1001014 Cite this Article Read Full Article PDF

Keywords:

COVID-19; Cytokine storm; Cholinergic anti-inflammatory pathway; Pyridostigmine

References

  1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579: 270-2730. PubMed: https://pubmed.ncbi.nlm.nih.gov/32015507/
  2. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382: 1708-1720. PubMed: https://pubmed.ncbi.nlm.nih.gov/32109013/
  3. Chen N, Zhou M, Dong X, Qu J, Gong F, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395: 507-513. PubMed: https://pubmed.ncbi.nlm.nih.gov/32007143/
  4. Xu Z, Shi L, Wang Y, Zhang J, Huang L, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Me. 2020; 8: 420-422. PubMed: https://pubmed.ncbi.nlm.nih.gov/32085846/
  5. Tracey KJ. Physiology and immunology of the cholinergic anti-inflammatory pathway. J Clin Invest. 2007; 117: 289-296. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1783813/
  6. Severe Acute Respiratory Syndrome. https://www.cdc.gov/sars/about/fs-sars.html
  7. Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science. 2003; 302: 276–278. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12958366
  8. Lau SK, Woo PC, Li KS, Huang Y, Tsoi HW, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc. Natl Acad Sci USA. 2005; 102: 14040–14045. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16169905
  9. Li W, Shi Z, Yu M, Ren W, Smith C, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science. 2005; 310: 676–679. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16195424
  10. Zheng BJ, Wong KH, Zhou J, Wong KL, Young BW, et al. SARS-related virus predating SARS outbreak, Hong Kong. Emerg Infect Dis. 2004; 10: 176–178. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322899/
  11. Middle East Respiratory Syndrome Coronavirus. http://www.who.int/ emergencies/mers-cov/en/
  12. Raj VS, Farag EA, Reusken CB, Lamers MM, Pas SD, et al. Isolation of MERS coronavirus from a dromedary camel, Qatar, 2014. Emerg Infect Dis 2014; 20: 1339–1342. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25075761 
  13. Conzade R, Grant R, Malik MR, Elkholy A, et al. Reported Direct and Indirect Contact with Dromedary Camels among Laboratory- Confirmed MERS-CoV Cases. Viruses. 2018; 10: E425. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30104551
  14. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395: 565–574. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32007145
  15. Coronavirus disease (COVID-2019) situation reports. 2020. https:// www.who.int/emergencies/diseases/novel-coronavirus-2019/situationreports
  16. Lee N, Hui D, Wu A, Chan P, Cameron P, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003; 348: 1986–1994. PubMed: PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12682352
  17. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013; 13: 752–761. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23891402
  18. Wang H, Xiao X, Lu J, Chen Z, Li K, et al. Factors associated with clinical outcome in 25 patients with avian influenza a (H7N9) infection in Guangzhou, China. BMC Infect Dis. 2016; 16: 534. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27716101
  19. Huang C, Wang Y, Li X, Ren L, Zhao J, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497–506. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31986264
  20. Tortorici MA, Veesler D. Structural insights into coronavirus entry. Adv Virus Res. 2019; 105: 93–116. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31522710
  21. Zhang N, Jiang S, Du L. Current advancements and potential strategies in thedevelopment of MERS-CoV vaccines. Expert Rev Vaccines. 2014; 13: 761–774. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24766432
  22. Xia S, Zhu Y, Liu M, Lan Q, Xu W, et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol. 2020; 1-3. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32047258
  23. Yu F, Du L, Ojcius DM, Pan C, Jiang S. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect. 2020; 22: 74-79. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32017984
  24. de Wilde AH, Snijder EJ, Kikkert M, van Hemert MJ. Host factors in coronavirus replication. Curr Top Microbiol Immunol. 2018; 419: 1–42. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28643204
  25. Sawicki SG, Sawicki DL. Coronavirus transcription: a perspective. Curr Top Microbiol Immunol. 2005; 287: 31–55. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15609508
  26. Hussain S, Pan J, Chen Y, Yang Y, Xu J, et al. Identification of novel subgenomic RNAs and noncanonical transcription initiation signals of severe acute respiratory syndrome coronavirus. J Virol. 2005; 79: 5288–5295. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15827143
  27. Perrier A, Bonnin A, Desmarets L, Danneels A, Goffard A, et al. The C-terminal domain of the MERS coronavirus M protein contains a trans- Golgi network localization signal. J Biol Chem. 2019; 294: 14406–14421. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31399512
  28. Wu F, Zhao S, Yu B, Chen YM, Wang W, et al. A new coronavirus associated with human respiratory disease in China, Nature. 2020; 579: 265-269. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32015508
  29. Jeffers SA, Tusell SM, Gillim-Ross L, et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus, Proc. Natl. Acad. Sci. U. S. A. 2004; 101: 15748-15753. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15496474
  30. Vacchelli E, Galluzzi L, Eggermont A. et al. Trial Watch: immunostimulatorycytokines. Oncoimmunology. 2012; 1: 493–506.
  31. Dendorfer U. Molecular biology of cytokines. Artif Organs. 1996; 20: 437–444. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/8725624
  32. Wang D, Hu B, Hu C, Zhu F, Liu X, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323: 1061-1069. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32031570
  33. Todd NW, Luzina IG, Atamas SP. Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogenesis Tissue Repair. 2012; 5: 11. https://www.ncbi.nlm.nih.gov/pubmed/22824096
  34. Chen C, Zhang XR, Ju ZY, He WF. Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies. Zhonghua Shaoshang Zazhi. 2020; 36: E005. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32114747
  35. Liu Y, Zhang C, Huang F, Yang Y, Wang F, et al. 2019-novel coronavirus (2019-nCoV) infections trigger an exaggerated cytokine response aggravating lung injury. 2020. http://www.chinaxiv.org/abs/202
  36. Williams AE, Chambers RC. The mercurial nature of neutrophils: still an enigma in ARDS? Am J Physiol Lung Cell Mol Physiol. 2014; 306: L217-230. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24318116
  37. Cameron MJ, Bermejo-Martin JF, Danesh A, et al. Human immunopathogenesis of severe acute respiratory syndrome (SARS), Virus Res. 2008; 133: 13-19. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17374415
  38. K. Min, S. Cheon, N. Y. Ha, et al.,: Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity, Sci Rep. 2016; 6: 25359. PubMed: https://pubmed.ncbi.nlm.nih.gov/27146253/
  39. Xu Z, Shi L, Wang Y, Zhang J, Huang L, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome, Lancet Resp Med. 2020; 8: 420-422. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32085846
  40. Coggle JE, Lambert BE, Moores SR. Radiation effects in the lung. Environ Health Perspect. 1986; 70: 261–291. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/3549278
  41. Féréol S, Fodil R, Pelle G, Louis B, Isabey D. Cell mechanics of alveolar epithelial cells (AECs) and macrophages (AMs). Respir Physiol Neurobiol. 2008; 163: 3–16. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18565804
  42. Fehrenbach H. Alveolar epithelial type II cell: defender of the alveolus revisited. Respir Res. 2001; 2: 33-46. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59567/
  43. Tian S, Hu W, Niu L, Liu H, Xu H, et al. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. J Thorac Oncol. 2020; 5: 700-704. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32114094
  44. Xu Z, Shi L, Wang Y, Zhang J, Huang L, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020: 8: 420-422. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32085846
  45. Tian S, Hu W, Niu L, Liu H, Xu H, et al. Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020; 15: 700-704. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128866/
  46. Tracey KJ. Physiology and immunology of the cholinergic anti-inflammatory pathway. J Clin Invest. 2007; 117: 289-296. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1783813/
  47. Paiardini M, Müller-Trutwin M. HIV-associated chronic immune activation. Immunol Rev. 2013: 254: 78–101. https://www.ncbi.nlm.nih.gov/pubmed/23772616
  48. Moncunill G, Negredo E, Bosch L, Vilarrasa J, Witvrouw M, et al. Evaluation of the anti-HIV activity of statins. AIDS. 2005; 19: 1697–1700. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16184043
  49. Valdés-Ferrer SI, Crispín JC, Belaunzarán PF, Cantú-Brito CG, Sierra-Madero J, et al. Acetylcholine-esterase inhibitor pyridostigmine decreases T cell overactivation in patients infected by HIV. AIDS Res Hum Retroviruses. 2009; 25: 749–755. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19645607
  50. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, et al: Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000; 405: 458. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10839541
  51. Pavlov VA and Tracey KJ. Neural regulation of immunity: molecular mechanisms and clinical translation. Nat Neurosci. 2017; 20: 156–166. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28092663

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More